Sign in

    Steve Dechert

    Vice President and Equity Research Analyst at KeyBanc Capital Markets

    Steve Dechert is a Vice President and Equity Research Analyst at KeyBanc Capital Markets, specializing in healthcare services and medical technology research. He has recently covered companies such as Absci Corp and LifeStance Health, including issuing a notable $9.0 price target and 'Overweight' rating for LifeStance Health in April 2025, reflecting a strong engagement with earnings calls and coverage in this sector. Dechert's career includes multiple years of research experience, with industry registration as a broker at KeyBanc Capital Markets and a FINRA record under CRD# 6745454. He holds pertinent securities licenses and has previously served as a registered investment adviser, underscoring his professional credentials and regulatory standing.

    Steve Dechert's questions to Absci (ABSI) leadership

    Steve Dechert's questions to Absci (ABSI) leadership • Q2 2025

    Question

    Steve Dechert of KeyBanc Capital Markets asked about Absci's capacity for additional partnerships following the Almirall expansion and requested an update on the HIV collaboration with Caltech.

    Answer

    CFO Zach Jonasson assured that capacity is reviewed quarterly and that the company is well-positioned for new partnerships, aided by efficiencies from its AI platform. CEO Sean McClain reported no new updates on the Caltech HIV program, stating it is progressing well and is currently in Caltech's hands for their portion of the collaborative work.

    Ask Fintool Equity Research AI

    Steve Dechert's questions to Absci (ABSI) leadership • Q2 2025

    Question

    Steve Dechert of KeyBanc Capital Markets asked about Absci's capacity for new partnerships following the Almirall expansion and requested an update on the Caltech HIV collaboration.

    Answer

    CFO & CBO Zach Jonasson stated that capacity is reviewed quarterly and is sufficient for current and new partnerships, partly due to AI-driven efficiencies. CEO Sean McClain reported no new updates on the Caltech HIV program, noting it is progressing well and is currently with Caltech for their portion of the work.

    Ask Fintool Equity Research AI

    Steve Dechert's questions to LifeStance Health Group (LFST) leadership

    Steve Dechert's questions to LifeStance Health Group (LFST) leadership • Q2 2025

    Question

    Steve Dechert of KeyBanc Capital Markets asked about the timeline for realizing cost benefits from new AI tools and requested an update on the company's new EHR selection process.

    Answer

    CEO David Bourdon explained that AI tools for revenue cycle and scheduling are already contributing to efficiency and quality, driving long-term operating leverage rather than immediate, large cost reductions. He noted that the AI for clinician documentation is primarily aimed at improving satisfaction. He added that a decision on a new EHR is expected in the second half of 2025.

    Ask Fintool Equity Research AI

    Steve Dechert's questions to Certara (CERT) leadership

    Steve Dechert's questions to Certara (CERT) leadership • Q2 2025

    Question

    Steve Dechert of KeyBanc Capital Markets asked for specific reasons behind the slowdown in Tier 1 software renewals and inquired about the profitability profile of the QSP business relative to Certara's other offerings.

    Answer

    CFO John Gallagher attributed the Tier 1 software issue to the quarterly lumpiness of bookings and expressed high confidence in second-half renewals. Regarding QSP, he noted it is currently a services business with a typical services profitability profile and mentioned the upcoming launch of Certara IQ, a software product for QSP.

    Ask Fintool Equity Research AI

    Steve Dechert's questions to LifeMD (LFMD) leadership

    Steve Dechert's questions to LifeMD (LFMD) leadership • Q2 2025

    Question

    Steve Dechert of KeyBanc Capital Markets questioned the company's refund policy, the reasons for a higher refund rate in the quarter, and whether LifeMD still facilitates prescriptions for personalized (compounded) GLP-1s.

    Answer

    CEO Justin Schreiber described the refund policy as 'extremely liberal,' offering full refunds to patients who cannot access or afford therapy. He attributed the higher rate to the high cost of branded GLP-1s, which leads some patients without insurance to seek cheaper alternatives. He confirmed that providers can still prescribe personalized GLP-1s to third-party pharmacies when clinically appropriate.

    Ask Fintool Equity Research AI

    Steve Dechert's questions to Talkspace (TALK) leadership

    Steve Dechert's questions to Talkspace (TALK) leadership • Q2 2025

    Question

    Steve Dechert from KeyBanc Capital Markets asked about changes in marketing spend allocation and recent trends in reimbursement rate negotiations with payers.

    Answer

    CFO Ian Harris noted no material changes in core marketing allocation but mentioned testing new channels for Medicare and military audiences. CEO Jon Cohen stated that payer reimbursement rates are renegotiated every few years and, having recently completed a cycle, he does not anticipate any significant negotiations within the next year.

    Ask Fintool Equity Research AI

    Steve Dechert's questions to Talkspace (TALK) leadership • Q2 2025

    Question

    Steve Dechert from KeyBanc Capital Markets inquired about changes in marketing spend allocation and trends in reimbursement rate negotiations with payers.

    Answer

    CFO Ian Harris noted no material changes in core marketing allocation but mentioned testing new channels for the Medicare and military populations. CEO Jon Cohen stated that payer rate renegotiations occur every few years and nothing significant is expected within the next year.

    Ask Fintool Equity Research AI